A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SeLan
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 17 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2015 to 1 Apr 2015.